

01-94010-08

Original Effective Date: 04/15/03

Reviewed: 10/26/23

Revised: 11/15/23

Subject: Treatment of Hyperhidrosis

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

[Position Statement](#)

[Billing/Coding](#)

[Reimbursement](#)

[Program Exceptions](#)

[Definitions](#)

[Related Guidelines](#)

[Other](#)

[References](#)

[Updates](#)

DESCRIPTION:

Hyperhidrosis is defined as excessive sweating, beyond a level required to maintain normal body temperature, in response to heat exposure or exercise. It can be classified as primary or secondary.

Primary focal hyperhidrosis is idiopathic, typically involving the hands (palmar), feet (plantar), head or face (craniofacial), or axillae (underarms).

Secondary gustatory hyperhidrosis is excessive sweating on ingesting highly spiced foods. This trigeminovascular reflex typically occurs symmetrically on the scalp or face and predominately over the forehead, lips, and nose. Secondary facial gustatory occurs independently of the nature of the ingested food. This phenomenon frequently occurs after injury or surgery in the region of the parotid gland.

POSITION STATEMENT:

NOTE: For treatment of hyperhidrosis using botulinum toxin injections, please refer to [MCG 09-J0000-29 Botulinum Toxin](#).

Primary focal hyperhidrosis

Treatment of primary focal hyperhidrosis **meets the definition of medical necessity** for any of the following conditions:

- Acrocyanosis of the hands
- History of recurrent skin maceration with bacterial or fungal infections
- History of recurrent secondary infections

- History of persistent eczematous dermatitis despite medical treatments with topical dermatologic or systemic pharmacotherapy

The following treatments **meet the definition of medical necessity** for treatment of primary **focal** hyperhidrosis:

- Topical agents
- Systemic pharmacotherapy
- Surgical excision of axillary sweat glands, if conservative treatment with topical or systemic pharmacotherapy has failed
- Endoscopic transthoracic sympathectomy (ETS), if conservative treatment with topical or systemic pharmacotherapy has failed
- Iontophoresis

Severe secondary gustatory hyperhidrosis

The following treatments for severe secondary gustatory hyperhidrosis **meet the definition of medical necessity**:

- Topical agents
- Surgical options (e.g., tympanic neurectomy) if treatment with topical agents has failed

The following treatments for hyperhidrosis are considered **experimental or investigational**:

- Axillary liposuction
- Microwave treatment
- Radiofrequency ablation
- Lumbar sympathectomy

There is insufficient clinical evidence in the peer-reviewed literature to support conclusions regarding long-term safety, efficacy, or improvement in net health outcomes.

BILLING/CODING INFORMATION:

The following codes may be used to describe treatments for hyperhidrosis. There is no specific code describing surgical excision of the axillary sweat glands for hyperhidrosis.

CPT Coding:

32664	Thoracoscopy; with thoracic sympathectomy
69676	Tympanic neurectomy
97033	Iontophoresis, each 15 minutes

REIMBURSEMENT INFORMATION:

Refer to sections entitled [POSITION STATEMENT](#).

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage products: No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) was found at the time of the last guideline review date.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#).

DEFINITIONS:

Eccrine glands: any of the rather small sweat glands that produce a fluid secretion without removing cytoplasm from the secreting cells and that are restricted to the human skin (eccrine sweat gland).

Functional impairment: difficulties that substantially interfere with or limit role functioning in one or more major life activities (eg, may interfere with the ability to maintain appropriate hygiene, or may interfere with work in certain professions).

Gustatory: of or relating to the sense of taste. Gustatory hyperhidrosis conditions include Frey's syndrome, encephalitis, syringomyelia, diabetic neuropathies, herpes zoster parotitis and parotid abscess.

Iontophoresis: a technique that involves the use of an electric current to introduce various ions through the skin.

RELATED GUIDELINES:

[Botulinum Toxins, 09-J0000-29](#)

OTHER:

Index terms:

- Endoscopic sympathectomy
- Gustatory hyperhidrosis
- Hyperhidrosis
- Iontophoresis
- Sweating, excessive
- Sympathectomy, thoracic
- Thoracoscopic sympathectomy

REFERENCES:

1. American Association of Neurological Surgery (AANS) Position Statement: Sympathectomy for hyperhidrosis. February 2007 [Reaffirmed Nov. 2009] Accessed at: <http://www.aans.org>.
2. Arora G, Kassir M, Patil A, Sadeghi P, Gold MH, Adatto M, Grabbe S, Goldust M. Treatment of Axillary hyperhidrosis. *J Cosmet Dermatol*. 2022 Jan;21(1):62-70. doi: 10.1111/jocd.14378. Epub 2021 Aug 20.
3. Blue Cross Blue Shield Association Evidence Positioning System®. 8.01.19 - Treatment of Hyperhidrosis, 07/23.
4. Cerfolio RJ, De Campos JR, Bryant AS, Connery CP, Miller DL, DeCamp MM et al. The Society of Thoracic Surgeons Expert Consensus for the Surgical Treatment of Hyperhidrosis. *Ann Thorac Surg*. 2011 May;91(5):1642-8.
5. ClinicalTrials.gov. A Study to Compare Oxybutynin to a Placebo in Women and the Effect on Plantar Hyperhidrosis. NCT01328015. Federal University of São Paulo. 04/01/11.
6. ClinicalTrials.gov. Evaluation of Patients with Palmar Hyperhidrosis Submitted to Two Levels of Sympathectomy: T3 and T4. NCT01140659. University of São Paulo. 06/21/10.
7. ClinicalTrials.gov. Histological Analysis Following Ulthera System Treatment for Hyperhidrosis. NCT01708551. Ulthera, Inc. 01/18/13.
8. Coehlo et al. Bilateral Retroperitoneoscopic Lumbar Sympathectomy by Unilateral Access for Plantar Hyperhidrosis in Women. *J Laparoendosc Adv Surg Tech A*. 2010 Feb;20 (1):1-6.
9. ECRI Institute. Endoscopic Thoracic Sympathectomy for the Treatment of Hyperhidrosis. Plymouth Meeting (PA): ECRI Institute Health Technology Assessment Information Service; 2006 Oct. (Evidence Report; no. 136).
10. Gregoriou S, Sidiropoulou P, Kontochristopoulos G, Rigopoulos D. Management Strategies of Palmar Hyperhidrosis: Challenges and Solutions. *Clin Cosmet Investig Dermatol*. 2019; 12:733-744. Published 2019 Oct 4. doi:10.2147/CCID.S210973.
11. Hayes Medical Technology Directory: Endoscopic Sympathectomy Treatment for Hyperhidrosis 01/14/03; updated 02/15/08.
12. Hayes Search and Summary Report. Liposuction for Hyperhidrosis (08/16/07).
13. Hirakawa N, Higashimoto I, Takamori A, Tsukamoto E, Uemura Y. The impact of endoscopic thoracic sympathectomy on sudomotor function in patients with palmar hyperhidrosis. *Clin Auton Res*. 2021 Apr;31(2):225-230. doi: 10.1007/s10286-020-00685-2. Epub 2020 Apr 27. Erratum in: *Clin Auton Res*. 2020 May 25.
14. Hong HC, Lupin M, O'Shaughnessy KF. Clinical Evaluation of a Microwave Device for Treating Axillary Hyperhidrosis. *Dermatol Surg* 2012; 38:728–735.
15. Hornberger J, Grimes K, Naumann M et al; Multi-Specialty Working Group on the Recognition, Diagnosis, and Treatment of Primary Focal Hyperhidrosis. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. *J Am Acad Dermatol* 2004; 51(2):274-86.
16. Kim et al. Chemical Lumbar Sympathetic Block in the Treatment of Plantar Hyperhidrosis: A Study of 69 Patients. *Dermatol Surg*. 2008 Oct;34(10):1340-5. Epub 2008 Jun 30.
17. Kisielnicka A, Szczerkowska-Dobosz A, Purzycka-Bohdan D, Nowicki RJ. Hyperhidrosis: disease aetiology, classification, and management in the light of modern treatment modalities. *Postepy Dermatol Alergol*. 2022 Apr;39(2):251-257. doi: 10.5114/ada.2022.115887. Epub 2022 May 9.
18. Loureiro et al. Endoscopic lumbar sympathectomy for women: effect on compensatory sweat. *Clinics (Sao Paulo)*. 2008 Apr; 63(2): 189-96.
19. Misiak P, Jabłoński S, Rzepkowska-Misiak B, Piskorz L, Brocki M, Wcisło S, Smigielski J, Kordiak J. Evaluation of the effectiveness of thoracic sympathectomy in the treatment of primary hyperhidrosis

of hands and armpits using the measurement of skin resistance. *Videosurgery Miniinv* 2012; 7 (3): 147-155.

20. Mostafa TAH, Hamed AA, Mohammed BM, El Sheikh NA, Shama AAA. C-Arm Guided Percutaneous Radiofrequency Thoracic Sympathectomy for Treatment of Primary Palmar Hyperhidrosis in Comparison with Local Botulinum Toxin Type A Injection, Randomized Trial. *Pain Physician*. 2019;22(6):591-599.
21. Naumann M, So Y, Argoff CE, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2008;70: 1707. Perera E, Sinclair R. Hyperhidrosis and bromhidrosis -- a guide to assessment and management. *Aust Fam Physician*. 2013 May;42(5):266-9.
22. Park JM, Moon DH, Lee HS, Park JY, Lee JW, Lee S. Hyperhidrosis, Endoscopic Thoracic Sympathectomy, and Cardiovascular Outcomes: A Cohort Study Based on the Korean Health Insurance Review and Assessment Service Database. *Int J Environ Res Public Health*. 2019;16(20):3925. Published 2019 Oct 15. doi:10.3390/ijerph16203925.
23. Rajagopal R, Mallya NB. Comparative evaluation of botulinum toxin versus iontophoresis with topical aluminium chloride hexahydrate in treatment of palmar hyperhidrosis. *Med J Armed Forces India*. 2014 Jul;70(3):247-52. doi: 10.1016/j.mjafi.2014.01.008. Epub 2014 Apr 26.
24. Rieger et al. Endoscopic lumbar sympathectomy for plantar hyperhidrosis. *Br J Surg*. 2009 Dec; 96(12): 1422-8.
25. Rieger et al. Retroperitoneoscopic lumbar sympathectomy for the treatment of plantar hyperhidrosis: technique and preliminary findings. *Surg Endosc*. 2007 Jan; 21(1):1 29-35. Epub 2006 Sep 6.
26. Saenz JW, et al. FPIN's clinical inquiries. Treatment of hyperhidrosis. *Am Fam Physician*. 2011 Feb 15;83(4):465-6.
27. Schlereth T, Dieterich M, Birklein F. Hyperhidrosis—Causes and Treatment of Enhanced Sweating. *Deutsches Ärzteblatt International* 2009; 106(3): 32–7.
28. Şener S, Karakoç Y. Effects of Direct Current Administration on Hyperhidrosis Disease Severity Scale in Patients with Axillary Hyperhidrosis. *Biomed Res Int*. 2019; 2019:3232015. Published 2019 Oct 31. doi:10.1155/2019/3232015.
29. Solish, Nowell MD, FRCPC, et al. "A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the canadian hyperhidrosis advisory committee". *Dermatol Surg* 33 (2007): 908-923.
30. Stefaniak T, Cwigoń M, Laski D. In the Search for the Treatment of Compensatory Sweating. *The Scientific World Journal* Volume 2012, Article ID 134547.
31. Stoleman, LP, MD, FACP< FRCP (C). Hyperhidrosis Medical and Surgical Treatment. *Eplasty*. 2008; 8: e22. Published online 2008 April 18.
32. The Society of Thoracic Surgeons. Expert Consensus for the Surgical Treatment of Hyperhidrosis. *Ann Thorac Surg* 2011; 91:1642–8.
33. UpToDate. Primary focal hyperhidrosis. 2023. Accessed at uptodate.com.
34. U.S. Food and Drug Administration (FDA). Center for Devices and Radiological Health (CDRH). MiraDry System (K103014), approved January 28, 2011. Accessed at <http://www.accessdata.fda.gov/> on 02/20/13.
35. U.S. Food and Drug Administration (FDA). Medical & Radiation Emitting Device Recalls: MiraDry System, Class II Recall (Z-2591-2011); recalled on June 27, 2011. Accessed at <http://www.accessdata.fda.gov/>.

36. Wand F, Chen Y, Yang W, Shi L. Comparison of compensatory sweating and quality of life following thoracic sympathetic block for palmar hyperhidrosis: electrocautery hook versus titanium clip. Chinese Medical Journal 2011;124(21):3495-3498.
37. Wolosker N, Milanez de Campos JR, et al. The use of oxybutynin for treating facial hyperhidrosis. An Bras Dermatol. 2011;86(3):451-6.
38. Yaghobi Z, Goljarian S, Oskouei AE. Comparison of tap water and normal saline iontophoresis in idiopathic hyperhidrosis: a case report. J Phys Ther Sci. 2014 Aug;26(8):1313-5. doi: 10.1589/jpts.26.1313. Epub 2014 Aug 30.
39. Yoshida et al. Chemical lumbar sympathectomy in plantar hyperhidrosis. Clin Auton Res. 2009 Dec 11.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 10/26/23.

GUIDELINE UPDATE INFORMATION:

04/15/03	New Medical Coverage Guideline.
05/15/04	Scheduled review; added coverage statement for surgical excision of sweat glands for axillary hyperhidrosis; added investigational statement for axillary liposuction.
04/15/06	Scheduled review; no change in coverage statement; added cross-reference statement regarding Botox injections for treating hyperhidrosis; removed aluminum chloride from the list of treatments discussed in this MCG; added “refractory to standard medical treatment” to the coverage statement in When Services Are Covered.
04/15/07	Scheduled review; no change in coverage statement.
06/15/07	Reformatted guideline.
04/15/08	Scheduled review; no change in position statement. Updated references.
04/15/09	Scheduled review. Update references and position statement with addition of indication for the use of Botox.
04/15/10	Annual review; investigational position statement for chemical or surgical lumbar sympathectomy added to guideline. References updated.
10/15/10	Revision; related ICD-10 codes added.
04/15/12	Scheduled review. Position statement maintained. Revised description section, ICD10 coding and definitions. Updated references.
04/15/13	Scheduled review. Revised description and position statement (designated microwave treatment for hyperhidrosis as experimental or investigational). Revised ICD9 coding, definitions and index terms. Updated references and reformatted guideline.
02/15/14	Revision; Program Exceptions section updated.
11/01/15	Revision: ICD-9 Codes deleted.
10/01/16	Revision: Billing/Coding Information section updated.
10/15/18	Scheduled review. Revised description and position statement. Updated programs exceptions and references.
09/15/20	Scheduled review. Revised description, position statement, and CPT coding. Updated references.

12/15/21	Scheduled review. Revised description, maintained position statement and updated references.
05/22/23	Update to Program Exceptions section.
11/15/23	Scheduled review. Maintained position statement and updated references.